(HealthDay)—For patients with very severe acute respiratory distress syndrome (ARDS), 60-day mortality is not significantly lower with venovenous extracorporeal membrane oxygenation (ECMO) than with continued conventional treatment, according to a study published online in the May 24 issue of the New England Journal of Medicine. Alain Combes, M.D., Ph.D., from the Sorbonne Université in Paris,